

# CanREValue

Value-based decisions from Real World Evidence

---

## Fall 2021 Newsletter

---

Issue 12 | Fall 2021

### Study Objectives:

#### Objective 1: (ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally
- ❖ Keep current on emerging/new information related to RWE in Canada and beyond

#### Objective 2: (established & ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

#### Objective 3: (ongoing)

- ❖ Validate the developed framework through the completion of a multi-province RWE project

#### Objective 4: (ongoing)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework

### CANREVALUE 2021 GOES VIRTUAL

While we have begun recovery following the worst of the COVID-19 pandemic, we are not yet ready to return to in-person events. Accordingly, we have made the decision to hold the 2021 Annual CanREValue Meeting virtually, following the success of our virtual 2020 meeting. The virtual CanREValue Virtual Annual Meeting will be held on October 7, 2021 for members of the CanREValue Collaboration. We will partner with ARCC to hold a webinar during the 2021-2022 webinar series to provide a public update on work to date, including an update on the Virtual Annual Meeting.

Please email us at [CanREValue@cc-arcc.ca](mailto:CanREValue@cc-arcc.ca) if you have any questions or need additional information.

### CANREVALUE PATIENT ENGAGEMENT – ENGAGEMENT WORKING GROUP

On August 24, 2021 the Engagement Working Group brought together a group of patient groups and individual patient representatives to review and obtain feedback on key patient issues relating to the Policy WG Interim Report. Due to the overwhelming feedback received, we are scheduling a second consult to continue reviewing the key policy feedback / issues

and key data issues reflected in the Data WG Interim Report. The second patient engagement session will be scheduled later in 2021 and will be shared once confirmed. Contact [CanREValue@cc-arcc.ca](mailto:CanREValue@cc-arcc.ca) should you have any questions regarding the Patient Engagement sessions or the Engagement Working Group.



## WORKING GROUP UPDATES AND NEXT STEPS:

Working Group	Updates & Next Steps
Planning and Drug Selection	<p><b>Updates:</b></p> <ul style="list-style-type: none"><li>• Conducted a MCDA workshop in May 2021</li><li>• In collaboration with PAG, we initiated a demonstration project evaluating the MCDA process on August 18, 2021 (MCDA Soft Launch)</li></ul> <p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Continue assessing the MCDA rating tool. The next soft launch will be scheduled later in 2021.</li></ul>
Data	<p><b>Updates:</b></p> <ul style="list-style-type: none"><li>• Abstracts on the real-world effectiveness and cost-effectiveness from ON are accepted at CADTH2021 and CCRC 2021 ,</li><li>• Held 3 interprovincial meetings to discuss analytical issues in each province and to prepare for the annual meeting</li><li>• Manuscript titled “Comparative effectiveness and safety of pertuzumab, trastuzumab, plus chemotherapy vs trastuzumab plus chemotherapy for metastatic breast cancer patients: a real-world population-based retrospective study conducted by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration” submitted and under review</li><li>• Manuscript titled “Comparative cost-effectiveness of pertuzumab, trastuzumab, plus chemotherapy vs trastuzumab plus chemotherapy for metastatic breast cancer patients: a real-world population-based retrospective study conducted by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration” submitted and under review</li></ul> <p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Continue with real-world analysis in 9 provinces</li></ul>
Methods	<p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Consult and discuss appropriate methodology for next identified outcome measure</li><li>• Continue support of Data WG on 9 province analysis</li></ul>
Reassessment and Uptake	<p><b>Updates:</b></p> <ul style="list-style-type: none"><li>• Exploring the opportunities to operationalize Step 4 through a demonstration project.</li><li>• Manuscripts on the updates from R&amp;U WG have been accepted by Current Oncology</li><li>• Manuscript on the Mock Reassessment exercise with the WG members currently submitted and under review.</li></ul> <p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Continue working with WG members and relevant stakeholders to further develop the RWE Implementation Plan</li></ul>
Engagement	<p><b>Updates:</b></p> <ul style="list-style-type: none"><li>• Held a patient engagement consultation on August 24, 2021 with 24 patient representatives</li></ul> <p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Draft summary report from initial patient engagement consultation &amp; circulate</li><li>• Planning second patient engagement consultation for late Fall 2021.</li></ul>



## MEMBER SPOTLIGHT – CAROLINE MUÑOZ, RESEARCH ASSOCIATE, PHARMACOECONOMICS RESEARCH UNIT, ONTARIO HEALTH

### **Q: What is your educational background and how did it lead to an interest in RWE?**

I completed my BSc in Life Sciences at McMaster University. Afterwards I spent a couple years working at McMaster University on clinical trials and academic research projects. My academic and professional experiences led me to pursue a graduate degree in epidemiology. I completed my MSc in Community Health and Epidemiology at Dalhousie University which included a thesis focused on vaccine safety, specifically vaccination in patients with adverse events following prior vaccinations.



My background in epidemiology combined with my years of working on clinical trials led me very nicely to RWE. I am looking forward to applying evidence-based research methods to answer questions about real world effectiveness and cost-effectiveness of cancer therapies.

### **Q: What aspect of the CanREValue project are you the most excited to work on?**

I have been most interested in better understanding how cost-effectiveness analyses are conducted. Specifically, I'm most excited to learn about the nuances of using real-world effectiveness and cost data and the methodologies used to take that data and turn it into meaningful outcomes.

### **Q: What has been the most interesting aspect of this project for you so far?**

The most interesting aspect of this project has been the CanREValue Collaboration Framework. I have been very fortunate to join the CanREValue team in the weeks leading up to the Annual meeting and, because of this timing, have been included in many meetings focused on the Framework. I'm looking forward to learning more about the collaborative roles of the Working Groups and being apart of discussions that move the Framework into its next stage of development.

**Q: How can we reach you?** You can email me at [caroline.munoz@ontariohealth.ca](mailto:caroline.munoz@ontariohealth.ca)

## Recent Publications/Presentations:

### **Publications:**

Beca, J. M., W. F. Dai, R. E. Pataky, D. Tran, E. Dvorani, W. Isaranuwachai, S. Peacock et al. "Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces." *Clinical Oncology* (2021):Aug 26 S0936-6555(21)00295-8.

Pataky, Reka E., Jaclyn Beca, David Tran, Wei Fang Dai, Erind Dvorani, Wanrudee Isaranuwachai, Stuart Peacock et al. "Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces." *MDM Policy & Practice* 6, no. 1 (2021): 23814683211021060.



## **Presentations:**

Dai, Wei Fang, Jaclyn Marie Beca, Chenthila Nagamuthu, Ning Liu, Maureen E. Trudeau, Craig Earle, Claire De Oliveira, and Kelvin K. Chan. "Real-world cost-effectiveness of pertuzumab (P) with trastuzumab+ chemo (T+ Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration." (ASCO 2021): 1048-1048.

Dai, Wei Fang, Jaclyn Marie Beca, Chenthila Nagamuthu, Ning Liu, Maureen E. Trudeau, Craig Earle, Claire De Oliveira, and Kelvin K. Chan. "Real-world cost-effectiveness of pertuzumab with trastuzumab in patients with metastatic breast cancer: population-based patient-level retrospective cohort study by the CanREValue collaboration." (ARCC 2021)

Dai, Wei Fang, Jaclyn Marie Beca, Chenthila Nagamuthu, Ning Liu, Maureen E. Trudeau, Craig Earle, Claire De Oliveira, and Kelvin K. Chan. "Real-world effectiveness and safety of pertuzumab with trastuzumab in patients with metastatic breast cancer: population-based patient-level retrospective cohort study by the CanREValue collaboration." (ARCC 2021)

